1 / 8

3D Screen Printing – An Innovative Technology

Three-dimensional (3D) screen printing was used to fabricate oral dosage forms of different geometry and size. The paste required as starting material for the 3D screen printing process was designed for delayed release and contained the model drug paracetamol (acetaminophen). A prototype screen printing unit was used to fabricate different tablets in a single production process. https://www.laxxonmedical.com/post/3d-screen-printing-an-innovative-technology-for-manufacturing-of-pharmaceutical-dosage-forms

diz
Download Presentation

3D Screen Printing – An Innovative Technology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Strategic Commercialization

  2. Patent Extension Laxxon offers pharmaceutical companies whose products are facing patent expiration an opportunity to “extend” their patents through Technology Transfer. Our additive manufacturing approach allows for the optimization and reformulation of such pharmaceutical products which, in turn, are protected by the Laxxon IP.

  3. Our “Patent Extension” through Technology Transfer solution is for registered pharmaceutical drugs on the market. Laxxon's technology optimizes the product and generates a new registration Launch of new product generation as the ancestral product is coming off patent Rebranding efforts transfer sales to new improved product generation New and improved patented product prevents any loss of sales Generates new and potentially higher revenue from optimized product

  4. Advanced Patented Generics Through SPID®-Technology, we can repurpose, reposition, and then relaunch generic APIs with patent protection while also addressing common generic drug issues such as patient compliance, dosage, and side effects. Our Advanced Patented Generics are going to be registered in the US under the FDA Section 505(b)(2), a fast-tracked regulatory approval process. In the EU, our Advanced Patented Generics will be registered as the Hybrid applications under Article 10(3) of Directive 2001/83/EC.

  5. The ideal 505(b)(2) candidates are: Drugs with changes in dosage form, strength, formulation, dosing regimen or route of administration Drugs with Drugs with new indications New combination product Prodrugs of an existing drug new active ingredients (in some cases)

  6. New Drug Development Laxxon serves as a research, development, engineering, and manufacturing partner for pharmaceutical companies seeking new drug development. SPID®- Technology can produce small batch sizes for R&D and clinical studies, which can then be scaled to an industrial standard of production without a change in the manufacturing process.

  7. Laxxon offers state-of-the-art manufacturing and cutting-edge, patented pharmaceutical solutions for external partners and in-house product development. Laxxon's technology can provide the ability to create new drug delivery systems using APIs previously incompatible with conventional manufacturing processes.

More Related